Knowledge-Based Shield Against New Wave of COVID19

COVID19 pandemic has made human, who had learned the ways of preventing, confronting and even eradicating many viral infections, suddenly face with the fear of not being able to control the disease and the lack of effective drugs.

Despite the 24/7 efforts made by experts and researchers to make vaccines and antiviral drugs, the glimmers of hope have gradually returned to the human society, which was immersed in mandatory isolation for many months.

Accordingly, the researchers of one of the knowledge-based companies have produced a drug with the aim of preventing, treating and reducing the symptoms of COVID19 patients; a drug that, in addition to domestic licenses, has recently obtained a patent certificate in the World Intellectual Property Organization (WIPO) and its production will soon begin in other countries as well.

While vaccines train the body's immune system to recognize and attack a virus that it has not faced before, antiviral drugs prevent the disease from continuing in various ways, such as preventing the virus from entering host cells and replicating or spreading to other cells.

The knowledge-based company that produces this antiviral drug has taken a difficult and complicated path to obtain the exclusive right of the invention; because in addition to a challenging process, innovation and uniqueness are the most important factors in the global patenting of a drug.

Elaborating on the invention of this drug, the World Intellectual Property Organization said: This invention is based on the "biological modeling" approach. Biological modeling or systems biology is one of the achievements of the synergy of science and technology, especially the integration of biology, information technology, medical sciences and systems in the last five decades.

Systems Biology opens new and promising horizons in medical sciences and pharmaceuticals.

" Saleh Ramezani, the technical director of this knowledge-based company, says: "This medicine was made using the design of natural pharmaceuticals, or pharmacognosy (the study of drugs derived from plants, microorganisms and the extraction of their constituent compounds, instead of chemical compounds). This medicine has no analogues in the world, neither in terms of system nor in terms of compounds.

Meanwhile, according to the article of this drug, which was published in the medical publications Elsevier and the NCBI database, the coronavirus has 29 different proteins, 13 of which are deactivated by this drug.

According to the report of the US Food and Drug Administration, among antiviral drugs, "remdesivir" is one of the most effective drugs licensed in the United States and other countries.

With the comparison made between the drug produced in this company and remdesivir, remdesivir has inhibitory power on eight of the 29 proteins of the covid-19 virus.

In addition to strengthening the immune system, it has significant antiviral and anti-inflammatory effects.

This product can be effective in earning currency, but due to the lack of proper laws, we are facing many challenges to export raw materials to other countries, Ramezani said.

Of course, the Technology Trade Development Center of Pardis Technology Park has made a lot of efforts to export medicine, and in this regard, agreements have been made with some Asian countries.